First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies.

Published in:

Investigational New Drugs, 2021, v. 39, n. 4, p. 1047, doi. 10.1007/s10637-021-01081-x

By:

• Piha-Paul, Sarina A.;
• Thein, Kyaw Z.;
• De Souza, Paul;
• Kefford, Richard;
• Gangadhar, Tara;
• Smith, Christopher;
• Schuster, Shelly;
• Zamboni, William C.;
• Dees, Claire E.;
• Markman, Ben

Publication type:

Article